BACKGROUND AND OBJECTIVES: Increased systolic BP visit-to-visit variability (SBV) may be associated with higher overall mortality and cardiovascular events. However, few studies have examined these associations in patients with CKD, and the relation of SBV with CKD progression and ESRD has not been shown. This study analyzed the association of SBV with overall mortality, cardiovascular mortality, cardiovascular events, and renal events among individuals enrolled in the African American Study of Kidney Disease (AASK) trial. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: This was a prospective observational study of 908 participants during the trial phase of the AASK study, with at least 1 year of BP measurements available and followed for 3-6.4 years. SBV was calculated as the SD of the systolic pressure from five visits occurring 3-12 months after randomization. The association of SBV with risk of overall mortality, cardiovascular mortality, a composite of fatal and nonfatal cardiovascular events, and a composite of renal events was assessed using proportional hazards regression and adjusting for multiple potential confounders. RESULTS: Greater SBV was associated with higher overall mortality. The adjusted hazard ratio (95% confidence interval) was 2.82 (1.14-6.95) comparing the highest with lowest tertile of SBV. A similar comparison revealed that greater SBV was also associated with cardiovascular mortality (adjusted hazard ratio, 4.91; 1.12-21.50). SBV was associated with both the cardiovascular renal composite endpoints in unadjusted but not adjusted analyses. CONCLUSIONS: In African Americans with CKD, SBV is strongly and independently associated with overall and cardiovascular mortality.
RCT Entities:
BACKGROUND AND OBJECTIVES: Increased systolic BP visit-to-visit variability (SBV) may be associated with higher overall mortality and cardiovascular events. However, few studies have examined these associations in patients with CKD, and the relation of SBV with CKD progression and ESRD has not been shown. This study analyzed the association of SBV with overall mortality, cardiovascular mortality, cardiovascular events, and renal events among individuals enrolled in the African American Study of Kidney Disease (AASK) trial. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: This was a prospective observational study of 908 participants during the trial phase of the AASK study, with at least 1 year of BP measurements available and followed for 3-6.4 years. SBV was calculated as the SD of the systolic pressure from five visits occurring 3-12 months after randomization. The association of SBV with risk of overall mortality, cardiovascular mortality, a composite of fatal and nonfatal cardiovascular events, and a composite of renal events was assessed using proportional hazards regression and adjusting for multiple potential confounders. RESULTS: Greater SBV was associated with higher overall mortality. The adjusted hazard ratio (95% confidence interval) was 2.82 (1.14-6.95) comparing the highest with lowest tertile of SBV. A similar comparison revealed that greater SBV was also associated with cardiovascular mortality (adjusted hazard ratio, 4.91; 1.12-21.50). SBV was associated with both the cardiovascular renal composite endpoints in unadjusted but not adjusted analyses. CONCLUSIONS: In African Americans with CKD, SBV is strongly and independently associated with overall and cardiovascular mortality.
Authors: Keith M Diaz; Praveen Veerabhadrappa; Mohammed A Kashem; Deborah L Feairheller; Kathleen M Sturgeon; Sheara T Williamson; Deborah L Crabbe; Michael D Brown Journal: Hypertens Res Date: 2011-08-04 Impact factor: 3.872
Authors: Peter M Rothwell; Sally C Howard; Eamon Dolan; Eoin O'Brien; Joanna E Dobson; Bjorn Dahlöf; Neil R Poulter; Peter S Sever Journal: Lancet Neurol Date: 2010-03-11 Impact factor: 44.182
Authors: Zhibin Li; Harold Snieder; Shaoyong Su; Gregory A Harshfield; Frank A Treiber; Xiaoling Wang Journal: J Hypertens Date: 2010-04 Impact factor: 4.844
Authors: Janice Lea; Deanna Cheek; Denise Thornley-Brown; Lawrence Appel; Lawrence Agodoa; Gabriel Contreras; Jennifer Gassman; Jim Lash; Edgar R Miller; Otelio Randall; Xuelei Wang; William McClellan Journal: Am J Kidney Dis Date: 2008-03-20 Impact factor: 8.860
Authors: Keith M Diaz; Rikki M Tanner; Louise Falzon; Emily B Levitan; Kristi Reynolds; Daichi Shimbo; Paul Muntner Journal: Hypertension Date: 2014-07-28 Impact factor: 10.190
Authors: Elvira O Gosmanova; Margit K Mikkelsen; Miklos Z Molnar; Jun L Lu; Lenar T Yessayan; Kamyar Kalantar-Zadeh; Csaba P Kovesdy Journal: J Am Coll Cardiol Date: 2016-09-27 Impact factor: 24.094
Authors: Paul Muntner; Jeff Whittle; Amy I Lynch; Lisandro D Colantonio; Lara M Simpson; Paula T Einhorn; Emily B Levitan; Paul K Whelton; William C Cushman; Gail T Louis; Barry R Davis; Suzanne Oparil Journal: Ann Intern Med Date: 2015-09-01 Impact factor: 25.391